MARKET

SWTX

SWTX

Springworks Therapeutics, Inc.
NASDAQ
46.20
+0.04
+0.09%
After Hours: 46.16 -0.04 -0.09% 19:59 05/07 EDT
OPEN
46.22
PREV CLOSE
46.16
HIGH
46.27
LOW
46.10
VOLUME
7.57M
TURNOVER
--
52 WEEK HIGH
62.00
52 WEEK LOW
28.21
MARKET CAP
3.46B
P/E (TTM)
-13.2682
1D
5D
1M
3M
1Y
5Y
1D
Harmony Biosciences Holdings, Inc. (HRMY) Tops Q1 Earnings and Revenue Estimates
NASDAQ · 1d ago
Weekly Report: what happened at SWTX last week (0428-0502)?
Weekly Report · 2d ago
Notable healthcare headlines for the week: Gilead, CVS Health, Sanofi in focus
Seeking Alpha · 3d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 04/30 16:15
SpringWorks Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 04/30 12:48
HC Wainwright & Co. Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47
Benzinga · 04/30 12:41
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
Barchart · 04/30 10:57
SpringWorks Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 04/30 10:27
More
About SWTX
More
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Recently
Symbol
Price
%Change

Webull offers SpringWorks Therapeutics Inc stock information, including NASDAQ: SWTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SWTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SWTX stock methods without spending real money on the virtual paper trading platform.